Coenzyme Q10

Within the SIRIAM Platform, Coenzyme Q10 (CoQ10) is classified as a Regional Signature Component.

Unlike the Structural & Dermal Support Core, Release Core and Integration Core ingredients, CoQ10 is incorporated selectively into regional formulations according to their intended neurodermal objectives.

Within the SIRIAM formulation philosophy, CoQ10 contributes a highly characterised endogenous mitochondrial cofactor that complements the platform's emphasis on cellular resilience, oxidative balance and physiological tissue support.

Its inclusion reflects the SIRIAM principle of integrating biologically established endogenous molecules into region-specific neurodermal formulations while maintaining a clear distinction between systemic physiological evidence and topical pharmaceutical application.

Coenzyme Q10 (CoQ10), also known as ubiquinone, is a naturally occurring lipid-soluble quinone synthesised by virtually all human cells.

It plays an indispensable role within the mitochondrial electron transport chain, where it functions as an electron carrier between Complexes I and II and Complex III, thereby supporting oxidative phosphorylation and ATP production.

Beyond mitochondrial bioenergetics, CoQ10 also functions as an important endogenous antioxidant by:

scavenging reactive oxygen species (ROS);

regenerating oxidised Vitamin E;

protecting membrane phospholipids from lipid peroxidation;

maintaining mitochondrial membrane integrity;

supporting cellular redox homeostasis.

CoQ10 concentrations decline with:

increasing age;

chronic oxidative stress;

mitochondrial dysfunction;

statin therapy;

several chronic diseases.

Extensive clinical evidence supports oral CoQ10 supplementation for conditions including:

primary CoQ10 deficiency;

heart failure;

statin-associated myopathy;

migraine prevention;

selected mitochondrial disorders;

improvement of oxidative stress biomarkers.

Topical CoQ10 has also been investigated in dermatology.

Experimental and clinical studies suggest that topical CoQ10 may contribute to:

reduction of oxidative skin damage;

protection against photoageing;

improvement of epidermal barrier function;

stimulation of fibroblast activity;

enhancement of collagen homeostasis;

reduction of fine wrinkle formation.

Several controlled cutaneous topical studies have demonstrated improvements in skin smoothness and wrinkle depth following topical CoQ10 application.

However, published research primarily evaluates conventional cutaneous topical formulations rather than pharmaceutical neurodermal systems.

No published studies currently investigate Coenzyme Q10 within a region-specific neurodermal formulation architecture comparable to the SIRIAM Platform.

Accordingly, its inclusion reflects strong biological plausibility together with the architectural philosophy of the platform rather than direct evidence for this specific pharmaceutical application.

Within the SIRIAM Platform, Coenzyme Q10 functions as a Regional Signature Component.

Its architectural role is to contribute mitochondrial and antioxidant support to selected regional formulations while integrating seamlessly with the broader pharmaceutical platform architecture.

Future optimisation may refine concentration and lipid delivery systems according to pharmaceutical validation.